207 related articles for article (PubMed ID: 26425215)
1. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine.
Akhmetov I; Bubnov RV
EPMA J; 2015; 6():19. PubMed ID: 26425215
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic challenges facing pharmacogenomics.
Cohen J; Wilson A; Manzolillo K
Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
Akhmetov I; Bubnov RV
EPMA J; 2017 Dec; 8(1):5-15. PubMed ID: 28228864
[TBL] [Abstract][Full Text] [Related]
5. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics.
Garrison LP; Towse A
J Pers Med; 2017 Sep; 7(3):. PubMed ID: 28869571
[TBL] [Abstract][Full Text] [Related]
6. Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.
Simeonidis S; Koutsilieri S; Vozikis A; Cooper DN; Mitropoulou C; Patrinos GP
Front Pharmacol; 2019; 10():830. PubMed ID: 31427963
[No Abstract] [Full Text] [Related]
7. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT).
Canestaro WJ; Pritchard DE; Garrison LP; Dubois R; Veenstra DL
J Manag Care Spec Pharm; 2015 Aug; 21(8):700-12. PubMed ID: 26233542
[TBL] [Abstract][Full Text] [Related]
8. Success Factors for Scaling Up the Adoption of Digital Therapeutics Towards the Realization of P5 Medicine.
Prodan A; Deimel L; Ahlqvist J; Birov S; Thiel R; Toivanen M; Kolitsi Z; Kalra D
Front Med (Lausanne); 2022; 9():854665. PubMed ID: 35492346
[TBL] [Abstract][Full Text] [Related]
9. The Personalized Medicine Coalition: goals and strategies.
Abrahams E; Ginsburg GS; Silver M
Am J Pharmacogenomics; 2005; 5(6):345-55. PubMed ID: 16336000
[TBL] [Abstract][Full Text] [Related]
10. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
11. Molecular diagnostics and personalized medicine: value-assessed opportunities for multiple stakeholders.
Blair ED
Per Med; 2010 Mar; 7(2):143-161. PubMed ID: 29783325
[TBL] [Abstract][Full Text] [Related]
12. Assessing the value-adding impact of diagnostic-type tests on drug development and marketing.
Blair ED
Mol Diagn Ther; 2008; 12(5):331-7. PubMed ID: 18803431
[TBL] [Abstract][Full Text] [Related]
13. New trends and challenges in the European regulation of innovative medicines.
Enzmann H
Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
16. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe.
Wurcel V; Perche O; Lesteven D; Williams DA; Schäfer B; Hopley C; Jungwirth R; Postulka A; Pasmans R; Hermansson LL; Ott M; Glorioso V
Public Health Genomics; 2016; 19(3):137-43. PubMed ID: 27237134
[TBL] [Abstract][Full Text] [Related]
17. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
18. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
19. Individual health services.
Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
[TBL] [Abstract][Full Text] [Related]
20. A coalition to drive personalized medicine forward.
Munroe JB
Per Med; 2004 Dec; 1(1):9-13. PubMed ID: 29793218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
